OMEROS CORP Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain
OMEROS CORP (OMER) had Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain of $0 as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain · last filed 2025-05-15
- 2025-03-31: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $0.00.
- 2024-12-31: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $0.00.
- 2023-12-31: Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain $19.00K.
| Period end | Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain |
|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-15 |
| 2023-12-31 | $19.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |